Drugs / EGFR/HER2 Dual-Target CAR-NK Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07617805 | Mar 2026 → Mar 2027 expected | head and neck squamous cell carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR/HER2 Dual-Target CAR-NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07617805 ↗ |
| Modality | Cell therapy | “infusion of allogeneic EGFR/HER2 dual-target CAR-NK cells” NCT07617805 ↗ |
| Target | EGFR | “engineered to express a dual EGFR/HER2 chimeric antigen receptor” NCT07617805 ↗ |